共 50 条
- [4] Benefit-Risk assessment based on number needed to treat and number needed to harm: Atogepant vs. calcitonin gene-related peptide monoclonal antibodies JOURNAL OF HEADACHE AND PAIN, 2024, 25
- [6] Benefit–Risk Assessment of Galcanezumab Versus Placebo for the Treatment of Episodic and Chronic Migraine Using the Metrics of Number Needed to Treat and Number Needed to Harm Advances in Therapy, 2021, 38 : 4442 - 4460
- [9] Number Needed to Treat and Number Needed to Harm: Its Importance UNIVERSITAS MEDICA, 2021, 62 (02):